DEXCOM INC
For the period ended Jun 30, 2025. Filed Jul 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 30, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 5. Other Information
Trading Plans
During the three months ended June 30, 2025, the following Section 16 officers and directors adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense of Rule 10b5-1(c):
| Name | Title | Action | Action Date | Aggregate Number of Shares to be Sold | Expiration Date(1) |
|---|---|---|---|---|---|
| Kyle Malady | Director | Adoption | 6/6/2025 | 2,885 | 6/4/2026 |
| Jereme M. Sylvain | Executive Vice President, Chief Financial Officer | Adoption | 5/27/2025 | 12,899 | 5/27/2026 |
| (1) Each trading arrangement permitted or permits transactions through and including the date listed in the table. | |||||
Each of the Rule 10b5-1 trading arrangements disclosed in the above table was made in accordance with our insider trading policy. Transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.
During the three months ended June 30, 2025, none of our Section 16 officers or directors adopted, modified, orterminated a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.